OnCusp Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class oncology therapies, including antibody-drug conjugates (ADCs) and other targeted cancer treatments. Co-founded in 2021 by veterans from Merck, Novartis, and Daiichi Sankyo, the company advanced its lead asset CUSP06 — a CDH6-targeted ADC — into Phase 1 clinical trials and has raised $139M from investors including Novo Holdings and OrbiMed.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2024
Apr 2021
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
